Umea

• Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) with Atorvastatin (ATORGO) Pending
  2023-504654-35-00 4 Graves Ofthalmopathy
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa … Pending
  2024-513778-23-00 5 Colon and rectal cancer tumor stage II-III, tumor with somatic alterat
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• The Swedish Nationwide Clinical Trial to Facilitate Patient Access to Targeted Cancer Treatment based on Biomarker Profiling (FOCU.SE) Pending
  2024-516003-16-00 4 Advanced Cancer
• Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obst … Pending
  2024-518016-39-00 10 Respiratory tract diseases
• ProFertil Pending
  2024-518977-32-00 5 Breast Cancer, Acute Leukemia, Lymphomas (Hodgkin and non-Hodgkin) ans
• The REFINE study Pending
  2025-522133-66-00 5 Autoimmune Premature Ovarian Insufficiency
• Nordic PREdnisolon for VEstibular NeuriTis Study – an investigator-driven, triple blind, placebo controlled randomized trial Pending
  2025-522399-10-00 5 Vestibular neuritis
• Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vom … Pending
  2025-522529-36-00 5 Post-operative nausea and vomiting (PONV)
• Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending
  2025-522580-15-00 4 Amyotrophic Lateral Sclerosis (ALS)
• Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone … Pending
  2025-522756-97-00 4 COVID-19 and Severely Impaired B-cell Function
• Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG Pending
  2026-525324-26-00 4 Schizophrenia spectrum disorder (SSD)
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations … Recruiting
  2024-517102-29-00 5 2025-11-19 Intestinal Malabsorption
• A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting
  2024-512536-29-00 4 2025-02-28 Amyotrophic Lateral Sclerosis (ALS)
• A randomized study in testicular cancer without metastasis, comparing two different types of chemotherapy used to reduce the risk of relapse Recruiting
  2024-518399-29-00 5 2024-12-27 Testicular cancer
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• First-line catheter ablation for early treatment of Persistent (ongoing unless cardioverted) Atrial Fibrillation (AF) – a randomized study … Recruiting
  2023-505962-28-00 5 2024-05-08 Persistent symptomatic atrial fibrillation
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections

Showing 1–24 of 161 trials